BRPI0414622A - métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias - Google Patents

métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias

Info

Publication number
BRPI0414622A
BRPI0414622A BRPI0414622-0A BRPI0414622A BRPI0414622A BR PI0414622 A BRPI0414622 A BR PI0414622A BR PI0414622 A BRPI0414622 A BR PI0414622A BR PI0414622 A BRPI0414622 A BR PI0414622A
Authority
BR
Brazil
Prior art keywords
compound
pain treatment
methods
treatment methods
acute
Prior art date
Application number
BRPI0414622-0A
Other languages
English (en)
Inventor
Audra L Scully
Robert E Davis
Kimberly E Vanover
Luis Roberto Gardell
Jelveh Lameh
Nicholas Michael Kelly
Fabio Bertozzi
Vladimir Sherbukhin
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of BRPI0414622A publication Critical patent/BRPI0414622A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/16—Compounds containing any of the groups, e.g. aminoguanidine
    • C07C281/18—Compounds containing any of the groups, e.g. aminoguanidine the other nitrogen atom being further doubly-bound to a carbon atom, e.g. guanylhydrazones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pain & Pain Management (AREA)

Abstract

"MéTODOS DE IDENTIFICAçãO DE COMPOSTOS, MéTODO DE SELEçãO DE COMPOSTO, MéTODOS DE TRATAMENTO DE DORES AGUDAS E CRÈNICAS, COMPOSTOS E MéTODOS DE TRATAMENTO DE DORES NEUROPáTICAS OU INFLAMATóRIAS". A invenção descrita abaixo refere-se à descoberta do subtipo receptor de neuropeptídeo FF que media a nocicepção aguda e dores neuropáticas crónicas, compostos que interagem seletivamente com esse subtipo receptor e métodos de tratamento de dores agudas e dores neuropáticas crónicas.
BRPI0414622-0A 2003-09-25 2004-09-24 métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias BRPI0414622A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50613003P 2003-09-25 2003-09-25
US50800803P 2003-10-02 2003-10-02
PCT/US2004/031530 WO2005031000A2 (en) 2003-09-25 2004-09-24 Treating neuropathic pain with neuropeptide ff receptor 2 agonists

Publications (1)

Publication Number Publication Date
BRPI0414622A true BRPI0414622A (pt) 2006-11-07

Family

ID=34396293

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0414622-0A BRPI0414622A (pt) 2003-09-25 2004-09-24 métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias

Country Status (11)

Country Link
US (1) US20050136444A1 (pt)
EP (1) EP1687641A2 (pt)
JP (1) JP2007506435A (pt)
KR (1) KR20060088885A (pt)
AU (1) AU2004276812A1 (pt)
BR (1) BRPI0414622A (pt)
CA (1) CA2539753A1 (pt)
IL (1) IL174517A0 (pt)
MX (1) MXPA06003276A (pt)
RU (1) RU2006113941A (pt)
WO (1) WO2005031000A2 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005116640A2 (en) * 2004-05-24 2005-12-08 Ludwig-Maximilians- Universität München Identification of anti-prion drugs by high-throughput screening based on sift
AU2007276763B2 (en) * 2006-07-24 2011-03-17 University Of Maryland, Baltimore Heme oxygenase inhibitors and methods of therapeutic use
AU2007299738B2 (en) 2006-09-20 2013-03-28 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
EP3581169A1 (en) 2008-01-22 2019-12-18 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20120190751A1 (en) * 2009-07-31 2012-07-26 Ana-Mar Ab Compounds for treatments of inflammation
GB201300435D0 (en) 2013-01-10 2013-02-27 Medical Res Council Benzylideneguanidine Derivatives and Therapeutic Use for the Treatment of Protein Misfolding Diseases
CA2910756C (en) * 2013-05-01 2021-11-16 Neoculi Pty Ltd Compounds and methods of treating infections
ES2749657T3 (es) 2014-07-02 2020-03-23 Inflectis Bioscience Derivados de O-alquil-bencilidenguanidina y su uso terapéutico para el tratamiento de trastornos asociados a una acumulación de proteínas mal plegadas
EP3721877A1 (en) 2014-07-02 2020-10-14 InFlectis BioScience Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies
WO2016162689A1 (en) * 2015-04-08 2016-10-13 Medical Research Council Inhibitors and their uses
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
EP3583090A4 (en) 2017-02-14 2020-12-30 Research Triangle Institute, International PROLINE-BASED NEUROPEPTIDE FF RECEIVER MODULATORS
US20210177814A1 (en) 2018-05-09 2021-06-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of guanabenz or derivates thereof for the treatment of type i ifn-dependent pathologies
US20240293343A1 (en) 2023-02-13 2024-09-05 Inflectis Bioscience Benzylideneaminoguanidine derivatives as NR2B-selective NMDA receptor antagonists and their therapeutic applications

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707798A (en) * 1993-07-13 1998-01-13 Novo Nordisk A/S Identification of ligands by selective amplification of cells transfected with receptors
CA2233584A1 (en) * 1997-06-11 1998-12-11 Smithkline Beecham Corporation 7tm receptor hlwar77
US6262246B1 (en) * 1998-09-25 2001-07-17 Synaptic Pharmaceutical Corporation DNA encoding mammalian neuropeptides FF (NPFF) receptors and uses thereof
US20030139431A1 (en) * 2001-09-24 2003-07-24 Kawakami Joel K. Guanidines which are agonist/antagonist ligands for neuropeptide FF (NPFF) receptors
US20030176314A1 (en) * 2001-09-24 2003-09-18 Forray Carlos C. Compounds for the treatment of pain
US20050244896A1 (en) * 2002-04-02 2005-11-03 Stefan Golz Diagnostics and therapeutics for diseases associated with neuropeptide ff receptor 2 (npff2)

Also Published As

Publication number Publication date
RU2006113941A (ru) 2007-10-27
CA2539753A1 (en) 2005-04-07
EP1687641A2 (en) 2006-08-09
US20050136444A1 (en) 2005-06-23
IL174517A0 (en) 2006-08-01
KR20060088885A (ko) 2006-08-07
WO2005031000A2 (en) 2005-04-07
MXPA06003276A (es) 2006-06-08
JP2007506435A (ja) 2007-03-22
WO2005031000A3 (en) 2005-07-14
AU2004276812A1 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
BRPI0414622A (pt) métodos de identificação de compostos, método de seleção de composto, métodos de tratamento de dores agudas e crÈnicas, compostos e métodos de tratamento de dores neuropáticas ou inflamatórias
NO20033918D0 (no) Ny anvendelse av peptidklasse av forbindelser for behandling av allodyni eller andre typer av kronisk smerte eller fantomsmerte
LUC00217I2 (pt)
MA30673B1 (fr) Composes et procedes d'inhibition de l'interaction de proteines bcl avec des partenaires de liaison
ATE431833T1 (de) Verwendung einer peptidartigen verbindung zur behandlung von neuropathischen entzündlichen schmerzerscheinungen
MA31067B1 (fr) Composés et procédés permettant d'inhiber l'interaction des protéines bcl avec des partenaires de liaison.
CL2007003594A1 (es) Compuestos derivados de heterociclos condensados de nitrogeno, inhibidores de transcriptasa inversa no nucleosidicos; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento del sida.
MXPA03006729A (es) Utilizacion de compuestos de azetidinona sustituida para el tratamiento de la sitosterolemia.
DK1420058T3 (da) Hurtig termisk processering af svære carbonhydrid-födeströmme i nærvære af calciumforbindelser
WO2003055979A3 (en) ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
EP2119443A4 (en) COMPOSITION FOR THE PREVENTION OR TREATMENT OF DISEASES RELATED TO A THROMBUS OR EMBOLUS
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
WO2003105840A3 (en) Sphingosine kinase inhibitors
BRPI0516533A (pt) método para o tratamento, inibição da progressão ou a erradicação da doença do rim policìstico em um mamìfero que dele necessita; produto; uso de um composto inibidor da tace; composição farmacêutica para o tratamento, a inibição da progressão ou a erradicação da doença do rim policìstico em um mamìfero
DE50214414D1 (de) Verschlusselement
BRPI0508084A (pt) método para o tratamento de um distúrbio neurológico, e, uso de meridamicina ou um sal do mesmo
BRPI0716428A2 (pt) Compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem, método para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de "sst" do subtipo 5 e uso destes compostos
MA26252A1 (fr) Usine flottante de traitement d'hydrocarbures.
DE50112878D1 (de) Nachweis von pathogenen bakterien
HU0201394D0 (pt)
SE0302361D0 (sv) Inhibering av upptagning av monoamin
ITRM20030567A1 (it) Apparato per lo spostamento assiale di tubature o simili.
BR0208784A (pt) Método para tratar, inibir a progressão ou erradicar a doença renal policìstica em um mamìfero em necessidade do mesmo
ATE455270T1 (de) Korrosionsbeständige leitungssysteme mit verbesserter oberflächenhärte
WO2003006385A3 (de) Textiles material für den einsatz in einer biologischen kläranlage

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.